agree. I’m big on looking at comparable trials to see how recruitment went as that’s often a good guide to the scale of the challenge . Take MPACT panc cancer trial I referred to before (gemcitabine + abraxane) . The published study says it took about 3 years with 150 sites to get 860 patients. That’s about 2 patients per site per year. Unless you think there’s a reason why ACCENT can substantially outperform MPACT , then I’d be using that estimate as a guide.
If that plays out here, with 11 sites, then could take at least a year to get this 26….
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-44
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.004(5.41%) |
Mkt cap ! $19.01M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.0¢ | $14.65K | 195.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51009 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 52133 | 1 |
View Market Depth
| Last trade - 15.59pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.004 ( 4.05 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.3¢ | 7.0¢ | 2121 | ||
| Last updated 15.08pm 05/06/2024 ? | |||||
| ATX (ASX) Chart |